• 首页
  • 报告
  • 资讯
  • 快讯
  • 图表
  • 网址导航
首页行业分类医疗健康2023-05-19-西南证券-新华医疗-聚焦主业提升毛利,研发投入持续增长
PDF

2023-05-19-西南证券-新华医疗-聚焦主业提升毛利,研发投入持续增长

我*****8 4页 1.1M

下载文档
/ 4
全屏查看
2023-05-19-西南证券-新华医疗-聚焦主业提升毛利,研发投入持续增长
还有 4 页未读 ,您可以 继续阅读 或 下载文档
报告派所有资源均由用户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1、本文档共计 4 页,下载后文档不带水印,支持完整阅读内容或进行编辑。
2、当您下载文档后,并不意味着拥有了版权,文档仅供网友学习交流,不得用于其他商业用途。
3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!
4、本本所有内容不构成任何投资建议,不具有任何指导和买卖意见。
5、如文档内容存在违规,或者侵犯商业秘密、侵犯著作权等,请点击“违规举报”。
新单医疗(600587)2022年年报点评2022A2023E2024E2025E2022A2023E2024E2025E9281.7710061.4410977.0312096.68529.21793.29964.331161.85营业成本6827.787344.858035.188830.58折旧与摊销233.01240.62247.56248.95营业税金及附加67.6273.1079.8187.9636.63201.23-54.8960.48销售货用887.471408.601207.471330.64-51.85200.00-200.00-200.00461.35503.07658.62604.83经营营运黄本变动-229.39-2271.94.154.21-256.99研发货用181.0050.3154.8960.48其他-129.56331.50141.41284.10财务货用36.63-201.23-54.89-60.48388.05.1307.76944.211177.44-51.85-200.00-200.00-200.00-127.35-50.00-50.0050.0049.73.100.000.000.00-153.8896.530.000.00公允价值变动损益-43.360.000.000.00-281.22-146.53-50.00-50.000.000.000.000.0060.01786.79-706.85-892.78585.83982.741195.941442.6837.660.000.000.00-9.748.879.479.6461.450.000.000.00576.09991.611205.411452.32支付股利0.00-100.52-150.68-183.17所得税46.89198.32241.08290.46-131.3185.1254.8960.48529.21793.29964.331161.8527.81771.38-802.65-1015.4726.6039.8848.4758.40136.04682.9091.56111.97502.61753.41915.851103.452022A2023E2024E2025E2022A2023E2024E2025E1689.051006.141097.701209.67成长能力应收和预付款项2235.732333.732553.902823.76-2.11%8.40%9.10%10.20%存货3028.723265.143666.213986.30-18.66%67.75%21.69%20.63%431.52290.81308.15329.35-4.82%49.90%21.56%20.48%1551.401551.401551.401551.40BTDA增长率-15.58%19.48%35.85%17.47%317.75317.75317.75317.752469.582305.812135.111963.01毛利率26.44%27.00%26.80%27.00%无形资产和开发支出747.29733.66720.03706.4014.93%17.00%16.50%15.50%其他非流动资产480.95467.72454.50441.275.70%7.88%8.78%9.60%12951.9812272.1712804.7413328.90ROE9.14%12.31%13.28%14.10%短期借款986.401773.181066.33173.55ROA4.09%6.46%7.53%8.72%应付和预收款项2899.132829.733164.683498.30ROIC15.79%12.65%15.04%17.89%长期借款96.3396.3396.3396.339.22%10.16%12.65%13.48%其他负债3180.831126.361217.181321.827162.685825.595544.525090.000.760.800.880.93股本411.97466.87466.87466.874.284.565.035.921722.951668.051668.051668.05应收账款周转率4.744.834.914.923285.173938.064703.235623.51存货周转率2.482.272.292.295393.136010.536775.707695.98116.45%少数股东权益396.17436.05484.52542.925789.306446.587260.228238.9055.30%47.47%43.30%38.19%12951.9812272.1712804.7413328.9015.12%32.09%20.97%5.30%流动比率1.071.241.441.732022A2023E2024E2025E速动比率0.630.650.750.90EBITDA855.471022.131388.621631.15股利支付率0.00%13.34%16.45%16.60%PE30.1420.1116.5413.73PB2812.522.241.971.081.611.962.36PS1.631.511.381.2511.5512.8714.5116.48EV/EBITDA13.3714.299.957.85每股经营现金0.83-2.802.022.520.00%0.66%0.99%1.21%每股股利0.000.220.320.39请务必阅读正文后的重要声明部分